Climate Change Data

Environmental Metrics

ESG Focus Areas

• Governance
• Clinical trial conduct
• Business ethics
• Economic performance
• Patient health and safety
• Responsible sourcing
• Diversity and inclusion
• Pay equality and wage level
• Talent attraction and retention
• Wellbeing of employees
• Occupational health and safety
• Climate and Environmental management

Environmental Achievements

• Started mapping GHG emissions to develop baselines for setting emission targets. Total emissions in 2021 were 17.54 tonnes CO2e.

Social Achievements

• Implemented a supplier self-assessment questionnaire based on the Pharmaceutical Supply Chain Initiative (PSCI) standard.
• Employee engagement survey conducted in 2021 had a 75% response rate with an engagement score of 80%.
• No occupational safety-linked incidents occurred in 2021.
• At year-end, 46 people were employed, of which 63% are women. Three out of eight executives in the management team are women, whilst two out of the six members of the Board of Directors are women.

Governance Achievements

• Strengthened responsible supply-chain management.
• No incidents of corruption were reported in 2021.
• No critical inspection findings from regulators and no monetary claims were received in 2021.

Climate Goals & Targets

Environmental Challenges

• Implementation of the updated Code of Conduct was delayed.
• Business travel represents 66% of total emissions.
• The long-term impact of the COVID-19 pandemic remains unclear.
• The ability to conduct clinical trials at the expected pace is a risk factor in the evolving pandemic.

Mitigation Strategies

• Aim to have the updated Code of Conduct implemented in 2022.
• Continue to conduct digital meetings when possible to limit travel.
• A focused development strategy is employed in response to the geopolitical situation and its impacts on financial market conditions.

Supply Chain Management

Supplier Audits: 10 key suppliers undertook a supplier ESG self-assessment

Responsible Procurement

• Supplier self-assessment questionnaire based on PSCI standard.

Climate-Related Risks & Opportunities

Reporting Standards

Frameworks Used: GRI, TCFD, UN SDGs

UN Sustainable Development Goals

• SDG 3
• SDG 8
• SDG 9
• SDG 12
• SDG 17

BerGenBio contributes to SDG 3 through its drug development, SDG 8 through decent work and economic growth, SDG 9 through innovation and R&D, SDG 12 through responsible production and consumption, and SDG 17 through partnerships.

Environmental Metrics

ESG Focus Areas

• Governance
• Clinical trial conduct
• Business ethics
• Economic performance
• Patient health and safety
• Responsible sourcing
• Diversity and inclusion
• Pay equality and wage level
• Talent attraction and retention
• Skills for the future
• Wellbeing of employees
• Occupational safety
• Greenhouse gas emissions (GHG)
• Climate Change
• Protection of human and labor rights

Environmental Achievements

• Tracked energy consumption and corresponding emissions; total emissions in 2022 was 54,63 tons CO2e (2021: 17,54 tons CO2e).

Social Achievements

• Implemented a whistleblower policy with independent third-party reporting channel in 2022; updated Code of Conduct implemented in March 2023; completed implementation of a supplier self-assessment questionnaire based on the pharmaceutical sector standard (Pharmaceutical Supply Chain Initiative, PSCI) in 2022; at year-end, employed 29 people, of which 62% are women; three out of seven executives in the management team are women while two out of the five members of our Board of Directors are women; introduced a hybrid working model in 2022; no occupational safety-linked incident occurred at any of our facilities in 2022; sick-leave of 2.3% in 2022 compared to 1.4% in 2021.

Governance Achievements

• No incidents of corruption, money laundering or insider trading reported in 2022; no critical inspection findings from any regulators in 2022; no monetary claims received in 2022; Board consists of five non-executive members of which two are women. All of the members are independent.

Climate Goals & Targets

Environmental Challenges

• The long-term impact of the COVID-19 pandemic remains unclear; ability to conduct clinical trials at the expected pace is a risk factor in the evolving pandemic; clinical studies may not prove to be successful; timelines for completion of clinical studies are to some extent dependent on external factors outside the control of the Group, including resource capacity at clinical trial sites, competition for patients, etc.; financial success requires obtaining marketing authorization and achieving an acceptable reimbursement price for its drugs; there can be no guarantee that the drugs will obtain the selling prices or reimbursement rates foreseen; rapid and substantial technological change; highly competitive industry sector with many large players; patent and intellectual property risks; regulatory and commercial risks; funding and liquidity risk; impact of geopolitical situation and associated impacts on financial market conditions.

Mitigation Strategies

• Secured a shareholder loan facility of up to NOK 100 million from Meteva AS in October 2022; announced an equity funding, a partly guaranteed and underwritten right issue, with a minimum proceed of NOK 175 million in April 2023; continuously revised procedures and manuals to reflect best practice derived from experience or adopted through regulations; implemented a comprehensive set of relevant corporate manuals and procedures; continuously monitoring liquidity; developing systems to manage environmental risks as the company grows; initiating conversations with suppliers to collect data on indirect emissions; implementing a waste minimization plan; aligning business with the Norwegian Transparency Act.

Supply Chain Management

Supplier Audits: 11 key suppliers undertook a supplier ESG self-assessment questionnaire

Responsible Procurement

• Supplier self-assessment questionnaire based on PSCI standard; partnering with third parties who share our values of business ethics, social and environmental consciousness; due diligence with a focus on risks of human rights violations in the value chain.

Climate-Related Risks & Opportunities

Physical Risks

• Not disclosed

Transition Risks

• Not disclosed

Opportunities

• Not disclosed

Reporting Standards

Frameworks Used: GRI, TCFD, GHG Protocol, UN SDGs

Certifications: ISO 15190:2003, OSHA 3404

Third-party Assurance: Ernst & Young AS

UN Sustainable Development Goals

• SDG 3
• SDG 8
• SDG 9
• SDG 12
• SDG 17

Contribution to SDG 3 through drug development for aggressive diseases; contribution to SDG 8 through decent work and economic growth; contribution to SDG 9 through innovation and R&D; contribution to SDG 12 through responsible production and consumption; contribution to SDG 17 through partnerships with research organizations and academic institutions.

Sustainable Products & Innovation

• Bemcentinib and Tilvestamab (AXL inhibitors)

Awards & Recognition

• Not disclosed